The marketing campaign launched today is part of PURA’s recently launched hemp lifestyle brand initiative to engage hemp advocate consumers in an overall ecosystem designed to collectively expand the base of knowledge surrounding the economic and environmental benefits of hemp and in so doing grow the overall hemp market.
Just as Sun-Maid Raisins is a conduit for the sales of raisins from many raisin farmers, PURA plans to be a conduit for the sales of hemp from many hemp framers.
PURA has recently published a multimedia presentation on its overall hemp lifestyle brand strategy and Mr. Shibley has further elaborated on the hemp lifestyle brand strategy in a video interview conducted by CEO Roadshow.
The centerpiece of PURA’s hemp lifestyle strategy is a recently acquired 72-acre property in Farmersville, Texas where PURA plans to partner with consumer advocates and other hemp industry companies to build demonstrable hemp based products and services that expand market-wide awareness of hemp’s economic and environmental benefits.
PURA has already announced pharmaceutical and neurocritical hemp extraction partnership with PAO Group, Inc. (OTC Pink: PAOG) and co-packing partnership with Alkame Holdings, Inc. (OTC Pink: ALKM) that are key components of PURA’s overall hemp lifestyle brand initiative.
Sign up to receive the latest updates at www.purationinc.com.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
SOURCE Puration, Inc.
Adverty is granted US patent for in-game ad viewability technology BrainImpression™
STOCKHOLM, Nov. 24, 2020 /PRNewswire/ — Adverty AB (publ) has been granted a patent by the United States Patent and Trademark Office for its in-game ad viewability technology BrainImpression™; a groundbreaking method for determining ad viewability and impressions within complex gaming environments. The patented invention is one of the core functionalities of Adverty’s leading in-game advertising platform.
Adverty, the leading in-game platform for advertisers, agencies and game developers, today announces the notice of allowance for its in-game ad viewability technology patent by the United States Patent and Trademark Office. The technology, called BrainImpression™, is a groundbreaking method for determining ad viewability and ad impressions, for example, when an advert is considered as seen by the user, within complex computer-generated graphical environments such as two-dimensional and three-dimensional games.
Viewability is one of the most important metrics in brand advertising and several renowned brands tend to exclude websites and other advertising media with low viewability in their media plans. To help advertisers understand and publishers define how to count an ad as seen, the media industry has established standards on how to measure web-based ad viewability. In regards to in-game advertising viewability, the industry is still at its infancy, with Adverty taking an active role in helping both IAB and third party ad verification leaders define these industry-wide, sought-after standards.
“Our patented in-game viewability algorithm outlines one of the core functionalities in our cutting-edge ad platform. We use our knowledge and innovation to help define appropriate viewability standards for in-game advertising – something that will benefit the media industry and heighten the acceptance of this new ad format amongst advertisers”, says Niklas Bakos, CEO and founder at Adverty.
The BrainImpression™ patent covers and protects a method of deciding if an advertisement, displayed in a gaming environment and shown on a display, has been seen by a user. The method of decision is based on the ad size, time in view and position on display for the user. Depending on the size of the ad on display, the ad is classified as seen after various time intervals, triggering an ad impression by the system.
Furthermore, the patent covers specific methods for adverts in the three-dimensional gaming space, where viewing angles and incidence angles towards the ad and the user display determine how well the ad is visible at any given time. For example, an ad unit viewed from the side is not detected as quickly, if at all, depending on its viewing angle, compared to an ad unit seen from a straight angle. Moreover, an advert placed in the center of the field of view is classified as seen faster than an ad closer to the periphery with a higher angle of incidence.
The BrainImpression™ patent application was filed in March 2017 at a time when Adverty focused on future gaming platforms such as Virtual, Augmented and Mixed Reality. Over the years, the focus has shifted towards mobile games, the largest and fastest growing gaming platform globally. Altogether, Adverty has established a leading cross-platform framework for unobtrusive, in-game brand and performance advertising, allowing brands to connect with new audiences in unique ways.
With the company’s fundamental mission in mind, the patent US 16/499.258 / US20200110262A1 covers head-mounted displays, such as Virtual Reality headsets, Augmented Reality headsets and smart glasses. A continuing application to protect the invention for other displays such as mobile phone, tablet and TV screens has been submitted to the United States Patent and Trademark Office.
For further information, please contact:
Niklas Bakos, CEO
Phone: +46 733 28 1110
E-mail: [email protected]
This information is information that Adverty AB (publ) is obliged to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on the 24th of November 2020.
Augment Partners AB, phone +46 8-505 65 172, act as certified advisor/mentor for the company at NGM Nordic SME.
Adverty, the leading in-game platform, delivers seamless advertising to connect brands and people through its revolutionary display advertising technology built for games. The platform offers true in-game ad inventory at scale and allows content creators to monetise the complete experience with unobtrusive, easy-to-integrate, immersive ads. Founded in 2016, Adverty has offices in Stockholm, London and Lviv and works with advertisers, agencies and developers to unlock audiences and gaming revenue streams. More information at www.adverty.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Adverty AB
Evox Therapeutics expands its existing exosome patent portfolio
OXFORD, England, Nov. 24, 2020 /PRNewswire/ — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce that the Company has been granted another key patent by the European Patent Office (EPO). This new grant reinforces the Company’s leading position within field of exosome therapeutics and adds to the growing number of foundational patent families within the Evox IP portfolio.
The recently granted European patent (EP3463465) provides coverage for exosomes and methods of producing exosomes comprising an endogenous polypeptide-based release system for enabling luminal loading of soluble proteins inside an exosome. Such a release mechanism is important for optimal functional exosome-mediated delivery of soluble therapeutic proteins and enzymes into recipient cells.
Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented:
“We are pleased to have been granted another important patent within our rapidly growing therapeutic exosome patent estate. This patent provides broad protection for our internal pipeline programs, where we are using this approach to functionally deliver soluble enzymes into cells in order to correct rare metabolic diseases. It is also broadly applicable to delivery of other types of drug payloads where luminal loading inside an exosome is important.”
About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox uses its proprietary DeliverEXTM technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.
For further information visit: www.evoxtherapeutics.com
SOURCE Evox Therapeutics
OMRON Strengthens Engagement with AliveCor with Series E Investment, Reinforces Cross-company Alliance for Remote Cardiovascular Condition Management
KYOTO, Japan, Nov. 24, 2020 /PRNewswire/ — OMRON Healthcare Co., Ltd. announced on November 24 additional investment into AliveCor by its parent company, OMRON Corporation, as part of $65 million series E funding for the leader in AI-based personal electrocardiogram (ECG) technology. OMRON led this round of investment, reinforcing the cross-company collaboration that began in 2017. The companies continue to build on their global alliance to accelerate development of solutions for cardiovascular disease management and remote patient monitoring utilizing ECG technology.
“OMRON is committed to developing life-saving cardiovascular health technologies in pursuit of our ‘Going for Zero’ vision to eliminate heart attacks and strokes. It is a lofty goal and, as we said when we evolved our vision, we cannot do it alone. That is why we seek like-minded partners, like AliveCor, to advance our initiatives and work together to save lives,” said Isao Ogino, president and CEO of OMRON Healthcare.
“Over one billion adults are hypertensive worldwide (*1), and their risk of stroke is nearly five times greater (*2) if they also suffer from Afib (atrial fibrillation). Hypertension is also an underlying health condition which increases the risk of complications with COVID-19 (*3). The ability to monitor both blood pressure and heart rhythm at home is essential for early detection, treatment and management of these cardiovascular health conditions.
“Our alliance with AliveCor will help enhance our current technology portfolio and provide hypertensive patients and healthcare professionals with data that can save lives–a complete picture of patients’ cardiovascular health that can be achieved with personal remote monitoring technology used at home. We continue to explore and develop new technologies to enhance the accessibility of home monitoring that help people to manage their condition, and will engage partners like AliveCor to ensure this technology is best-in-market, further accelerating our remote patient monitoring business to achieve our goal, Going for Zero,” said Ogino.
OMRON’s expanded investment into AliveCor builds upon the companies’ ongoing collaboration. OMRON expanded its blood pressure monitor portfolio with the launch of “Complete” (TM) the first blood pressure monitor with ECG capability in a single device and the first FDA-cleared technology developed in collaboration with AliveCor in 2019. Currently available in the U.S. at OmronHealthcare.com and participating retailers, expanded distribution of Complete (TM) is expected in other regions globally during the company’s fourth quarter.
(*1)World Health Organization: Hypertension ( https://www.who.int/news-room/fact-sheets/detail/hypertension )
(*2)American Heart Association: High Blood Pressure, AFib and Your Risk of Stroke
(*3)CDC: People with Certain Medical Conditions ( https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html )
About OMRON Healthcare
Committed to helping people live more active and fulfilling lives, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy. Throughout its history, OMRON has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 110 countries. OMRON provides the world’s No.1 blood pressure monitors and the company’s additional core categories are respiratory care, pain management and wellness products. The company also develops remote patient-monitoring service in the field of cardiovascular condition management.
SOURCE OMRON Healthcare Co., Ltd.
Oslo, Los Angeles, Mexico et Budapest s’engagent à construire des bâtiments propres pour mener l’industrie du bâtiment vers un avenir durable
Dans la Clean Construction Declaration du C40, les maires s’engagent à révolutionner l’industrie mondiale de la construction et à la conduire vers un avenir plus durable afin de parvenir à “une vie prospère, résiliente et saine pour tous dans nos villes, en particulier pour nos communautés les plus vulnérables”.
L’industrie de la construction est actuellement responsable de plus de 23 % des émissions mondiales de GES et de 30 % de la consommation mondiale de ressources. „Business as usual” signifierait une dangereuse augmentation de la température mondiale de 3°C.
La déclaration fixe des objectifs audacieux et ambitieux pour développer les bâtiments et les infrastructures du futur avec des émissions nettes zéro :
- Réduire les émissions indirectes d’au moins 50 % pour tous les nouveaux bâtiments et les rénovations d’ici 2030
- Réduire les émissions indirectes d’au moins 50 % de tous les projets d’infrastructure d’ici 2030
- Acquisition et, si possible, utilisation de machines de construction exclusivement sans émissions à partir de 2025.
L’obligation de convertir et de moderniser le parc immobilier existant présente un énorme potentiel de création de nouveaux emplois verts – essentiel pour une récupération équilibrée et respectueuse de l’environnement à partir de COVID-19.
Les maires utiliseront leur pouvoir d’achat pour standardiser les équipements de construction à émission zéro, exiger la transparence et la responsabilité dans la chaîne d’approvisionnement, intégrer une politique de construction propre dans les procédures de conception, d’achat et de passation de marchés et dans les codes de construction. Les maires s’engagent à approuver au moins un projet emblématique de construction à émission zéro d’ici 2025 et à rendre compte chaque année des progrès réalisés.
Communiqué de presse complet à: https://www.c40.org/press_releases/clean-construction-declaration-launch
Hannah Prime, Media and Editorial Manager
+44 (0) 776 939 7801
SOURCE C40 Cities Climate Leadership Group
Litecoin Searching for Support After Falling from 2020 High
Wall Street needs to relax, as startups show remote work is here to stay
Bitcoin Worth $3B from PlusToken Ponzi Scam Seized by Chinese Authorities
Bitcoin Still Hunting for a Bottom After Losing Support
UK to set up ‘pro-competition’ regulator to put limits on big tech
Accendo Banco chooses global fintech infrastructure platform Nium to provide international money transfer capability
Facebook’s Libra to Launch Dollar-Pegged Stablecoin in January
The Basics: Popular Casino Games You Should Play
Black Friday Crypto Deals Aplenty While Bitcoin is at a Discount
The International Vaccine Institute Supports a Global Campaign to Reduce the Spread of Covid-19
T1 re-signs top laner Canna, extends contract until 2022
JinkoSolar to Report Third Quarter 2020 Results on December 7, 2020
EWPG Holding AB: Interim report for the period 1 January – 30 September 2020
Khan joins DAMWON as team’s new top laner
Different ways tech plays a key role in securing igaming platforms
Alibaba vies for a piece of China’s booming EV market
LONGi suministra 273MW de sus módulos solares a la mayor planta solar del Sureste de Asia
Gift Guide: Black Friday tech deals that are actually worth checking out
Super Smash Bros. Melee Slippi mod launches broadcast feature early in response to #FreeMelee
The 7 best low-back gaming chairs
Heroic move past Endpoint in BLAST Premier Showdown
How cloud computing can empower e-commerce
Na’Vi brings Mag back from inactive roster to coach Dota 2 team
Fantasy games live for DreamHack Masters Winter and Flashpoint 2 playoffs
Worldwide Hybrid Diesel Genset Industry to 2026 – Key Drivers and Restraints
Facebook’s latest ad tool fail puts another dent in its reputation
The Neutrino Energy Group Transcends the Theoretical to Transform Practical Energy Use Worldwide
How to activate crossplay on Rainbow Six Siege
Pokémon teases 25th-anniversary celebration during Macy’s Thanksgiving Day Parade
ChemPoint es seleccionado como distribuidor de los productos de Soluciones Especializadas de DuPont para México
Energy4 days ago
ADAMA Mourns Death of Joe Krkoska, Executive Vice President of Global Operations
Blockchain7 days ago
Ethereum on a Tear as It Breaks New Yearly High
Nano Technology1 week ago
CCNY & partners in quantum algorithm breakthrough
Blockchain1 week ago
Ethereum 2.0 Sees $10 Million Stake from Dubai-Based Investment Firm
Blockchain1 week ago
Bitcoin Begins to Stall After Parabolic Ascent
Cyber Security6 days ago
Where Machine Learning Is Transforming Finance
Nano Technology1 week ago
Anions matter: Zinc-ion hybrid capacitors with ideal anions in the electrolyte show extra-long performance
Blockchain1 week ago
Deutsche Bank Says Investors Increasingly Prefer Bitcoin Over Gold as Inflation Hedge